Juan Pablo Solís
Vice President and General Manager in Mexico, Central America and the Caribbean
Becton Dickinson Mexico
View from the Top

The Answer to Top Health Concerns: Technology

Wed, 09/06/2017 - 11:50

Q: How important is Mexico to Becton Dickinson’s global position?

A: Mexico has long been a successful market for the company. The country is the second-largest market in Latin America after Brazil. Over the years we have gone from being a syringe company to taking up a leading position in clinical diagnosis, molecular chemistry and flow cytometry markets. Of Becton Dickinson's (BD) 45,000 global associates, 9,500 are Mexican, nearly 20 percent. They are distributed throughout our operations in Mexico City, San Luis Potosi, Sonora and Baja California. We export products made in Mexico to the US, Asia, Europe and the rest of Latin America. Our success in Mexico can be explained through our commercial and manufacturing history of over 60 years.

Q: How has Becton Dickinson permeated the Mexican market to ensure continued growth?

A: 2016 was an important year for BD. Globally, it was the first year we operated with the integration of Carefusion, acquired in 2015. Carefusion has a strong portfolio of innovative products and with this alliance, the company widened its footprint around the world. In Mexico, BD consolidated its market leadership, focusing on providing solutions for the country’s main health issues. We are relevant in key fields such as women’s health and cancer — we produce the best technology for the early and accurate integrated diagnosis of cervical cancer. We continue to be an important player in healthcare worker safety, providing a wide range of products that make clinical and medical practices safer for Mexican professionals, and we are becoming more relevant in diabetes management, with a large percentage of patients using our specialized syringes and pen needles for their daily care.

Q: How can BD technology help to improve the effectiveness and productivity of the Mexican public healthcare system?

A: Many innovative medical device companies, including BD, offer a set of products that in the short-term may appear to be more expensive than traditional devices. However, the new features, such as safety for healthcare workers and for patients, bring benefits in the long-run for the healthcare system. If a patient can be treated with state-of-the-art medical devices, it is more likely he or she leaves the hospital sooner.

Q: What business models help keep high technology affordable for the public and private sectors?

A: We work on different axes, first generating local clinical evidence about the benefits of our innovative products to the healthcare system, then early adopters among public and private institutions embed the new technologies. Once a product is proven to work, the system tends to adopt it en masse. At Becton Dickinson, we have a wide range of products that are affordable depending on the need, which is why we play at different levels of the healthcare system, following our purpose to advance the world of health.

Q: What is Becton Dickinson doing to support the digitalization of the Mexican healthcare system?

A: We have several technologies that support healthcaresystem digitalization. Through our solutions for lab automation, for example, we can connect different instruments to link clinical results to a lab and a hospital database. Our value proposition in medication-management systems can help with drug/patient traceability that is so badly needed in our country to avoid medication errors.

Q: What type of technology have you developed for the protection of healthcare professionals?

A: We have developments designed to prevent accidental punctures. A traditional syringe has a barrel and a needle, so when nurses give an injection, they are vulnerable to punctures. With our system, once the injection is made, there is a mechanism activated by a spring that covers the needle. These security products have seen great acceptance in the private sector and we want to show the benefits of this line to public institutions. Our clinical evidence shows that using these products greatly benefits the entire healthcare system.